Invivyd

Q2 FY2026 EarningsQ2 FY26 results presented a mixed profile against consensus: revenue of $14.3M slightly missed the $14.4M expected (-0.81%), while GAAP EPS of -$0.14 was significantly worse than the -$0.11 consensus mean. Although PEMGARDA net product revenue grew 21% YoY, heavy clinical investment in the VYD2311 program led to a net loss of $44.4M, far exceeding the projected $27.0M loss. A key regulatory headwind emerged with the 12-month notice of EUA termination for PEMGARDA, shifting all strategic focus to the upcoming VYD2311 pivotal data readout in late Q3 2026.